Special Topics PharmArch - About Pharmaceutical, Medicine & Health More Topics
-
6 Factors that Cause Liquid Chromatography Peak Diffusion
The main differences gas chromatography (GC) and liquid chromatography (LC) are primarily due to the differences in the properties of gas and liquid.Below are 6 Factors that mainly Cause Liquid Chromatography Peak Diffusion.
-
Retagliptin Phosphate Tablets approved by China NMPA for type 2 diabetes
Jun,2023. Retagliptin Phosphate Tablets, the Class 1. New drug from Jiangsu Hengrui Pharmaceuticals Co., Ltd for the treatment of type 2 diabetes, is approved by China NMPA.
-
Different Types of Ampoules for Pharmaceutical Industry
Ampoule is a small glass container used to hold liquid medicine .There are many types of ampoules, here we briefly introduce different types of ampoules for pharmaceutical industry.
-
Understanding Off-Label Prescriptions for Obesity Management
In 2022, more than 40% of American adults were recorded as obese. Health experts find this high statistic very concerning as obesity’s harmful effects on the quality of life of many citizens are becoming apparent. Apart from the physical health risks associated with the condition, it also negatively impacts a person’s psyche and mental state. Thus, many turn to medical weight loss treatments for help. Obesity medication has become especially popular in recent years due to its proven efficacy. Studies state that certain obesity medications can influence up to 15% weight loss….
-
Eccogene Completes 180 Million CNY in Series B Round Financing
June, 2023,Eccogene (Shanghai) Co. Ltd. (Eccogene) announced that it has received 180 million yuan (approximately $25 million USD) in Series B financing.
-
KarXT: Karuna plans to submit a New Drug Application (NDA) this year
When will KarXT be available on the market? Karuna’s drug for schizophrenia,KarXT attracted public attention so much. Investors and patients have great concern on KarXT release date and KarXT FDA approval timeline. According to the most recent news, Karuna plans to submit a New Drug Application (NDA) for KarXT within this year.
-
REGORAFENIB: Gastrointestinal cancer drug legends
Regorafenib was first approved by the FDA in September 2012. It is an oral multi-kinase inhibitor developed by Bayer that targets angiogenic, stromal and oncogenic receptor tyrosine kinase. New application of it is also under research according to the public information [ClinicalTrials.gov Identifier: NCT03793361(Study ID Numbers EREMISS)
-
Ivonescimab: lung cancer treatment breakthroughs from AKESO
Ivonescimab (PD-1/VEGF BsAbs,AK112), developed independently by Akeso, Inc, is the world’s first PD-1/VEGF bispecific antibody for clinical trail. Ivonescimab injection(AK112) has received 3 breakthrough therapy designation(BTD) for NSCLC.
-
Data integrity: ALCOA and ALCOA PLUS
ALCOA and ALCOA PLUS principles are for Data integrity.
ALCOA: Attributable, Legible, Contemporaneous, Original, Accurate.
ALCOA PLUS: Complete, Consistent, Enduring, Available When Needed. -
JOYO PHARMA complete pre-C round of financing
June, 2023, Guangzhou JOYO Pharma Co., Ltd (JOYO PHARMA)announced that it has completed the pre-C round of financing of more than 100 million yuan.